Hepatitis C News

For patients with hepatitis C, universal screening and the integration of clinical pharmacists may improve access to direct-acting antiviral therapy and help patients achieve sustained virologic response, according to a poster presentation.

In patients with hepatitis C infection who failed treatment with Vosevi, retreatment with a regimen of Sovaldi plus Mavyret plus ribavirin for 16 to 24 weeks was safe and effective, researchers reported.

A simplified, rapid treatment model for hepatitis C virus improved cure rates and the cascade of care among young people who inject drugs, according to a recent study.

Patients with hepatitis C who achieved sustained virologic response through direct-acting antiviral therapy experienced a decrease in psychiatric hospitalizations after treatment, according to a presenter at The Liver Meeting Digital Experience.

In 2019, only 32% of children and youth who had tested positive for hepatitis C in British Columbia, Canada, had initiated treatment, according to data presented at The Liver Meeting Digital Experience.

When treated with direct-acting antiviral therapy, patients with chronic hepatitis C virus infection were at a lower risk for end-stage kidney disease and the composite of ESKD or death, according to a speaker at ASN Kidney week.

Tenofovir alafenamide therapy was safe, well-tolerated and prevented the transmission of hepatitis B virus from pregnant mothers to infants, according to research presented at The Liver Meeting Digital Experience.

Consultations, testing and treatment of hepatitis B and C virus fell significantly during the first year of the COVID-19 pandemic, with many centers seeing declines of more than 75% in all categories, according to a presentation.

Higher end-of-treatment hepatitis B e-antigen level correlated with nucleos(t)ide clinical relapse but did not correlate with relapse severity regardless of HBsAg level among patients with chronic hepatitis B virus, according to research.

The CDC’s Advisory Committee on Immunization Practices voted unanimously, 15-0, on Wednesday to recommend hepatitis B vaccination for all adults aged 19 to 59 years.